報價延遲最少15分鐘:2026/11/04 17:03 EST
盤後時段
|
||||
|
38.23 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
38.23
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.47/-1.46
|
|
企業價值
26.13B
|
| 資產負債 |
|
每股賬面淨值
5.86
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.26M
|
|
每股收益
0.11
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
